Ro-316233

Ro-316233

SCHEMBL624896

O=C1NC(=O)C(c2c[nH]c3ccccc23)=C1c1c[nH]c2ccccc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCB P05771 9/20 1.00
CDK4 P11802 3/20 1.00
CCND1 P24385 3/20 1.00
CDK2 P24941 3/20 1.00
PRKCA P17252 3/20 1.00
CCNE2 O96020 2/20 1.00
PRKACA P17612 2/20 1.00
PRKACG P22612 2/20 1.00
PRKACB P22694 2/20 1.00
CCNE1 P24864 2/20 1.00
CAMK2D Q13557 2/20 1.00
ABL1 P00519 2/20 1.00
SIRT2 Q8IXJ6 2/20 1.00
PRKD3 O94806 1/20 1.00
CCNB2 O95067 1/20 1.00
PRKCG P05129 1/20 1.00
CDK1 P06493 1/20 1.00
PIM1 P11309 1/20 1.00
CCNB1 P14635 1/20 1.00
PRKCH P24723 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ro-316233 SCHEMBL29373011 1.00 PRKCB (1.00) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL3148490 0.92 PRKCB (0.84) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL13917970 0.88 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL3908534 0.88 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL29756414 0.88 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL5333315 0.88 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL8167180 0.88 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL6098588 0.88 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL6823304 0.88 PRKCB (0.78) PRKCBCDK4CCND1CDK2PRKCA
SCHEMBL9085236 0.86 PRKCB (0.74) PRKCBCDK4CCND1CDK2PRKCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120044159-A Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application 河北北方学院 2025-05-27 CN claimed
US-20230201173-A1 SMAD4 Complex Inducers and Uses in Cancer Therapy UNIV EMORY (US) 2023-06-29 US claimed
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US claimed
US-20060099568-A1 Signals and molecular species involved in senescence SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2006-05-11 US claimed
WO-2004083202-A1 A PROCESS FOR THE PREPARATION OF INDOLYMALEIMIDES SUVEN LIFE SCIENCES LIMITED (IN) 2004-09-30 WO claimed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US claimed
EP-0397060-B1 Maleinimide derivatives and their use as medicines GOEDECKE AG (DE) 2001-11-21 EP claimed
EP-0397060-A2 Maleinimide derivatives and their use as medicines GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-11-14 EP claimed
CN-120044159-A Polygonatum sibiricum medicinal material species identification method based on polygonatum sibiricum characteristic compound and application 河北北方学院 2025-05-27 CN disclosed
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER OMEROS CORPORATION 2023-09-14 US disclosed
US-20230201173-A1 SMAD4 Complex Inducers and Uses in Cancer Therapy UNIV EMORY (US) 2023-06-29 US disclosed
EP-2211901-B2 VACCINATION WITH MULTIPLE CLADES OF H5 INFLUENZA A VIRUS SEQIRUS UK LTD (GB) 2023-04-26 EP disclosed
US-20230094365-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF SNAP BIO, INC. 2023-03-30 US disclosed
US-20230002784-A1 COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS ORCHARD THERAPEUTICS (EUROPE) LIMITED (GB) 2023-01-05 US disclosed
EP-0328026-B1 SUBSTITUTED PYRROLES F. HOFFMANN-LA ROCHE AG (CH) 1993-04-28 EP disclosed
EP-0397060-A3 MALEINIMIDE DERIVATIVES AND THEIR USE AS MEDICINES GÖDECKE AKTIENGESELLSCHAFT (DE) 1992-01-02 EP disclosed
US-5057614-A Antiinflammatory, immunology, bronchodilator agents, cardiovascular disorders HOFFMANN-LA ROCHE INC. (US) 1991-10-15 US disclosed
EP-0397060-A2 Maleinimide derivatives and their use as medicines GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-11-14 EP disclosed
EP-0397060-A2 Maleinimide derivatives and their use as medicines GÖDECKE AKTIENGESELLSCHAFT (DE) 1990-11-14 EP disclosed
EP-0328026-A1 Substituted pyrroles F. HOFFMANN-LA ROCHE AG (CH) 1989-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230094365-A1 PIM KINASE INHIBITOR COMPOSITIONS, METHODS, AND USES THEREOF PIM1, PIM3, PIM2 PRKCB 32/4885CDK4 198/4885CCND1 2406/4885
US-20230285556-A1 METHODS AND COMPOSITIONS FOR TREATING CANCER TP53, CD4, MCL1 PRKCB 1254/4885CDK4 904/4885CCND1 1166/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF PRKCB 1519/4885CDK4 50/4885CCND1 92/4885
US-20230002784-A1 COMPOSITIONS AND METHODS FOR MODIFYING EUKARYOTIC CELLS PHAX, CD4, POLM PRKCB 2881/4885CDK4 3915/4885CCND1 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.